Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7554141 | 0.85 | NOTUM (0.49) | NOTUMNPC1ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL4275949 | 0.85 | NOTUM (0.49) | NOTUMNPC1ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL7551953 | 0.82 | DRD2 (0.61) | DRD2DRD4NOTUMNPC1ALDH1A1 | |
| SCHEMBL23113116 | 0.75 | NOTUM (0.51) | NOTUMNPC1ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL8633111 | 0.75 | ACE (0.61) | ACE | |
| SCHEMBL29443075 | 0.75 | ACE (0.61) | ACE | |
| SCHEMBL20462830 | 0.75 | NOTUM (0.75) | NOTUMNPC1ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL15638317 | 0.75 | NOTUM (0.51) | NOTUMNPC1ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL28221747 | 0.75 | NOTUM (0.51) | NOTUMNPC1ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL25352128 | 0.74 | ACE (0.44) | DRD2DRD4NOTUMALDH1A1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020128274-A1 | Benzylpiperazinyl-indolinylethanones | NEUROGEN CORPORATION. | 2002-09-12 | — | — | US | disclosed |
| US-6355644-B1 | NERVOUS SYSTEM DISORDERS AND TREATMENT OF SCHIZOPHRENIA AND BIPOLAR DISORDER | NEUROGEN CORPORATION | 2002-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128274-A1 | Benzylpiperazinyl-indolinylethanones | GABRP, GABBR1, GABARAP | DRD2 30/4885DRD4 57/4885NOTUM 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.